- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03437551
Prevalence of DRP and DME Among Type 1 Diabetics Treated With Long-term Intensified Insulin Therapy
A Cross Sectional Study Assessing the Prevalence of Different Stages of Diabetic Retinopathy and Diabetic Macular Edema Among Type 1 Diabetic Patients Treated With Long-term Intensified Insulin Therapy
This study is designed to evaluate the prevalence of different stages of diabetic retinopathy and diabetic macular edema among patients suffering from type 1 diabetes (DM1) for 5 to 25 years and have been treated with intensified insulin therapy aiming near-normal blood glucose levels for the whole duration of disease.
Prevalence of different stages of diabetic retinopathy and diabetic macular edema is assessed using the modified Airlie House classification and the Early Treatment Diabetic Retinopathy Study (ETDRS) retinopathy severity scheme. Results of this study will provide the basis for designing further studies as well as staging and screening guidelines for diabetic retinopathy/diabetic macular edema.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Purpose: This study is designed to evaluate the prevalence of different stages of diabetic retinopathy and diabetic macular edema among patients suffering from type 1 diabetes for 5 to 25 years and have been treated with intensified insulin therapy aiming near-normal blood glucose levels for the whole duration of disease.
Objectives: The primary objective is to examine the prevalence (percentages) of the stages of diabetic retinopathy (DR) and diabetic macular edema (DME) within one cross-sectional examination. Key secondary/exploratory objectives are the prevalence (percentages) of the stages of diabetic macular edema (DME), the means of individual average 5year-/10year-/15year-/20year-/25year-HbA1c value (%) as a measure for long-term glycemic control, the means of individual average 5year-/10year-/15year-/20year-/25year-blood pressure (mmHg) as a measure for long-term blood pressure control, mean BCVA score, mean contrast sensitivity score, mean NEI-VFQ 25 score (for further details see section Objectives).
Study design: Non-interventional cross-sectional investigator initiated study. The study will be conducted at Vista Klinik Binningen/Switzerland (ophthalmological evaluations) and the Department of Endocrinology of the University Hospital Basel/Switzerland (patient recruitment).
Study population: All patients with DM Type 1 with a least 5 years and maximum 25 years disease duration and intensified insulin therapy for the whole duration of disease, who are currently in follow-up for their DM1 at Department of Endocrinology of the University Hospital Basel/Switzerland. In order to prevent selection bias, patients will be screened for enrollment consecutively. For In-/exclusion criteria see section Eligibility.
Investigational and reference therapy: None.
Assessments:
- Visual acuity measurements using the ETDRS-like testing charts at a test distance of 4 meters
- Contrast sensitivity
- Ophthalmic examinations (slit lamp exam with fundus biomicroscopy, intraocular pressure)
- High resolution optical coherence tomography (Spectralis-OCT)
- Stereoscopic fundus photography
- Fluorescein angiography
- NEI-VFQ 25 (25-item National Eye Institute Vision Function Questionnaire)
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Zürich, Switzerland
- Vista Diagnostics
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male or female patients >18 years of age who have signed an informed consent
- Patients with type 1 diabetes mellitus diagnosed between 5 and 25 years prior to screening who were on intensified insulin therapy (multiple daily insulin injections or insulin pump) from the beginning of the disease.
Exclusion Criteria:
- Patients with hypertension and a change in antihypertensive treatment within 2 months pre-enrollment should not be enrolled unless blood pressure is maintained for at least 1 month below 160/100 mm Hg by antihypertensive treatment.
- Patients with a history of chronic renal failure requiring dialysis or kidney transplantation if there is a risk for the patient to perform fluorescein angiography (discretion of the endocrinological investigator).
- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (>5 mIU/ml).
- History of allergy to fluorescein.
- Inability to obtain fundus photographs, fluorescein angiograms or OCT images of sufficient quality to be analyzed and graded.
- Inability to comply with study procedures.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
no intervention
Cross-sectional Observation study
|
cross-sectional ophthalmic examination
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
prevalence (percentages) of the stages of diabetic retinopathy (DR)
Time Frame: 2 hours (one cross-sectional examination only)
|
the outcome is evaluated for different patient groups relating to the duration of diabetic retinopathy disease (5-10 years, 11-15 years, more than 15 years)
|
2 hours (one cross-sectional examination only)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
prevalence (percentages) of the stages of diabetic macular edema (DME)
Time Frame: 2 hours (one cross-sectional examination only)
|
the outcome is evaluated for different patient groups relating to the duration of DM1 disease (5-10 years, 11-15 years, more than 15 years)
|
2 hours (one cross-sectional examination only)
|
means of individual average 5year-/10-years-/15year-/20year-/25year-HbA1c value (%)
Time Frame: 2 hours (one cross-sectional examination only) then see also in retrospective data from 5year-/10-years-/15year-/20year-/25year
|
as a measure for long-term glycemic control
|
2 hours (one cross-sectional examination only) then see also in retrospective data from 5year-/10-years-/15year-/20year-/25year
|
the means of individual average 5year-/10-years-/15year-/20year-/25year-blood pressure (mmHg)
Time Frame: 2 hours (one cross-sectional examination only) then see also in retrospective data from 5year-/10-years-/15year-/20year-/25year
|
as a measure for long-term blood pressure control
|
2 hours (one cross-sectional examination only) then see also in retrospective data from 5year-/10-years-/15year-/20year-/25year
|
mean BCVA score
Time Frame: 2 hours (one cross-sectional examination only)
|
the outcome is evaluated for different patient groups relating to the duration of DM1 disease (5-10 years, 11-15 years, more than 15 years)
|
2 hours (one cross-sectional examination only)
|
mean contrast sensitivity score
Time Frame: 2 hours (one cross-sectional examination only)
|
the outcome is evaluated for different patient groups relating to the duration of DM1 disease (5-10 years, 11-15 years, more than 15 years).
|
2 hours (one cross-sectional examination only)
|
mean NEI-VFQ 25 score
Time Frame: 2 hours (one cross-sectional examination only)
|
the outcome is evaluated for different patient groups relating to the duration of DM1 disease (5-10 years, 11-15 years, more than 15 years).
|
2 hours (one cross-sectional examination only)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Christian Pruente, MD, Vista Klinik Binningen
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DRP-2010-02 (ZH)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Insulin-Dependent Diabetes Mellitus 1
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
Stanford UniversityConvaTec Inc.CompletedInsulin Dependent Diabetes Mellitus 1United States
-
Samsung Medical CenterMinistry of Trade, Industry & Energy, Republic of Korea; Korea Evaluation Institute... and other collaboratorsCompletedDiabetes Mellitus | Insulin-dependent Diabetes Mellitus | Insulin HypoglycemiaKorea, Republic of
-
DreaMed DiabetesCompletedDiabetes Mellitus, Type 1 | Insulin-dependent Diabetes MellitusIsrael
-
National Institute of Diabetes and Digestive and...Completed
-
Xeris PharmaceuticalsCompletedDiabetes Mellitus, Type 1 | Insulin-dependent Diabetes MellitusUnited States
-
Wayne State UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Insulin DependentUnited States
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedDiabetes Mellitus | Insulin-dependent Diabetes MellitusUnited States
-
The University of Texas Health Science Center,...National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
Clinical Trials on cross-sectional observation
-
University of KielRecruiting
-
Vista KlinikUniversity Hospital, Basel, SwitzerlandCompletedInsulin-Dependent Diabetes Mellitus 1Switzerland
-
Mutah UniversityRecruitingFibromyalgia | Orthopedic DisorderJordan
-
University of LiegeKU LeuvenCompletedPeriodontitis | Dentulous | Abdominal Aorta Aneurism
-
Centre Hospitalier de CayenneCompleted
-
Fundació Sant Joan de DéuHospital del Mar Research Institute (IMIM)Not yet recruitingChildhood Obesity | Diet Habit
-
Centre Hospitalier de Cayenneuniversite de guyaneCompleted
-
King's College LondonGuy's and St Thomas' NHS Foundation TrustRecruitingAnxiety | Cognitive Symptom | Food Allergy | Food Allergy in ChildrenUnited Kingdom
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Singapore National Eye CentreSingHealth Translational Immunology and Inflammation Centre; TTSH Eye ClinicRecruitingDry Eye Syndrome | AutoimmunitySingapore